206 related articles for article (PubMed ID: 30055872)
41. A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.
Enblad G; Karlsson H; Gammelgård G; Wenthe J; Lövgren T; Amini RM; Wikstrom KI; Essand M; Savoldo B; Hallböök H; Höglund M; Dotti G; Brenner MK; Hagberg H; Loskog A
Clin Cancer Res; 2018 Dec; 24(24):6185-6194. PubMed ID: 30097433
[TBL] [Abstract][Full Text] [Related]
42. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells.
Shiozawa M; Chang CH; Huang YC; Chen YC; Chi MS; Hao HC; Chang YC; Takeda S; Chi KH; Wang YS
BMC Immunol; 2018 Aug; 19(1):27. PubMed ID: 30075754
[TBL] [Abstract][Full Text] [Related]
43. Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy.
Siegler EL; Zhu Y; Wang P; Yang L
Cell Stem Cell; 2018 Aug; 23(2):160-161. PubMed ID: 30075127
[TBL] [Abstract][Full Text] [Related]
44. Adoptive Cell Therapy in Treating Pediatric Solid Tumors.
Tesfaye M; Savoldo B
Curr Oncol Rep; 2018 Aug; 20(9):73. PubMed ID: 30069644
[TBL] [Abstract][Full Text] [Related]
45. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
46. Cancer immunotherapy with CAR-T cells - behold the future.
Graham C; Hewitson R; Pagliuca A; Benjamin R
Clin Med (Lond); 2018 Aug; 18(4):324-328. PubMed ID: 30072559
[TBL] [Abstract][Full Text] [Related]
47. [Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].
Zhou SY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):490-492. PubMed ID: 30060355
[TBL] [Abstract][Full Text] [Related]
48. Design considerations for early-phase clinical trials of immune-oncology agents.
Wages NA; Chiuzan C; Panageas KS
J Immunother Cancer; 2018 Aug; 6(1):81. PubMed ID: 30134959
[TBL] [Abstract][Full Text] [Related]
49. IL-21 Selectively Protects CD62L
Ngai H; Tian G; Courtney AN; Ravari SB; Guo L; Liu B; Jin J; Shen ET; Di Pierro EJ; Metelitsa LS
J Immunol; 2018 Oct; 201(7):2141-2153. PubMed ID: 30111631
[TBL] [Abstract][Full Text] [Related]
50. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges.
Zhao Z; Chen Y; Francisco NM; Zhang Y; Wu M
Acta Pharm Sin B; 2018 Jul; 8(4):539-551. PubMed ID: 30109179
[TBL] [Abstract][Full Text] [Related]
51. Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory.
Viaud S; Ma JSY; Hardy IR; Hampton EN; Benish B; Sherwood L; Nunez V; Ackerman CJ; Khialeeva E; Weglarz M; Lee SC; Woods AK; Young TS
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10898-E10906. PubMed ID: 30373813
[TBL] [Abstract][Full Text] [Related]
52. The biological basis and clinical symptoms of CAR-T therapy-associated toxicites.
Titov A; Petukhov A; Staliarova A; Motorin D; Bulatov E; Shuvalov O; Soond SM; Piacentini M; Melino G; Zaritskey A; Barlev NA
Cell Death Dis; 2018 Sep; 9(9):897. PubMed ID: 30181581
[TBL] [Abstract][Full Text] [Related]
53. The human lymph node microenvironment unilaterally regulates T-cell activation and differentiation.
Knoblich K; Cruz Migoni S; Siew SM; Jinks E; Kaul B; Jeffery HC; Baker AT; Suliman M; Vrzalikova K; Mehenna H; Murray PG; Barone F; Oo YH; Newsome PN; Hirschfield G; Kelly D; Lee SP; Parekkadan B; Turley SJ; Fletcher AL
PLoS Biol; 2018 Sep; 16(9):e2005046. PubMed ID: 30180168
[TBL] [Abstract][Full Text] [Related]
54. CAR T cells find strength in polyfunction.
Davila ML
Blood; 2018 Aug; 132(8):769-770. PubMed ID: 30139827
[No Abstract] [Full Text] [Related]
55. [Effect of PD-1 inhibitor Nivolumab on the proliferation and cytotoxicity of anti-CD19 chimeric antigen receptor T cells].
Zhu HB; Deng Q; Zhang R; Jiang YY; Meng JX; Zhao MF; Li YM; Cui R
Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):584-588. PubMed ID: 30122019
[No Abstract] [Full Text] [Related]
56. Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells.
An N; Hou YN; Zhang QX; Li T; Zhang QL; Fang C; Chen H; Lee HC; Zhao YJ; Du X
Mol Pharm; 2018 Oct; 15(10):4577-4588. PubMed ID: 30185037
[TBL] [Abstract][Full Text] [Related]
57. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
58. [The CAR-T cells are here].
Croizier C; Douge A; Bay JO; Lemal R
Bull Cancer; 2018 Sep; 105(9):743-745. PubMed ID: 30119830
[TBL] [Abstract][Full Text] [Related]
59. Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids.
Dijkstra KK; Cattaneo CM; Weeber F; Chalabi M; van de Haar J; Fanchi LF; Slagter M; van der Velden DL; Kaing S; Kelderman S; van Rooij N; van Leerdam ME; Depla A; Smit EF; Hartemink KJ; de Groot R; Wolkers MC; Sachs N; Snaebjornsson P; Monkhorst K; Haanen J; Clevers H; Schumacher TN; Voest EE
Cell; 2018 Sep; 174(6):1586-1598.e12. PubMed ID: 30100188
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
